- Data Covid-19 USA — Many young adults are foregoing Covid vaccines for a complex mix of reasons. Health officials are racing to find ways to change their minds.
- Data Covid-19 USA — U.S. experts weigh the risks for younger women and cases of a rare blood-clotting disorder, and lift the pause in giving the one-shot vaccine.
Top federal health officials said in interviews this week that the number of rare blood clotting disorders in recipients of the Johnson & Johnson vaccine has remained small.
After an early focus on AstraZeneca and months of turmoil, the European Union is pivoting away from the company’s vaccine. It has reached agreement for a faster rollout of the Pfizer-BioNTech shot.
An advisory committee debated the very few cases of a rare blood disorder and worried about the suspension’s effect on global needs for a one-shot, easy-to-ship vaccine.
Some public health officials fear that the pause on the Johnson & Johnson vaccine may fuel vaccine hesitancy and expose more Americans to a bigger danger: the coronavirus.
Out of an “abundance of caution,” the F.D.A. is advising doctors to pause the Johnson & Johnson vaccine while it investigates extremely rare blood clots.
In rare cases, an immune reaction has led to antibodies that caused a serious clotting disorder. But public health experts maintain the vaccine’s benefits far outweigh the risks for most people.
Britain said it would give alternative shots to people under 30, while the European regulator said it had found a ‘possible link’ with rare blood clots.
Once it became clear Germany was pausing, the pressure mounted on other governments to hold off as well, out of fear of seeming incautious and for the sake of a united front.
There is no evidence so far of a link between the AstraZeneca shots and a few new cases in Europe of serious illness and deaths. But investigations are underway.
- Protected: v36-new There is no excerpt because this is a protected post.